Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
UT Southwestern Medical Center
mi
from
Dallas, TX
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
University of Texas Southwestern University Hospital - Zale Lipshy
mi
from
Dallas, TX
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
University of Texas Southwestern University Hospital - Zale Lipshy
mi
from
Dallas, TX
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
University of Washington Medical Center
mi
from
Seattle, WA
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
LLUCC - Records Management Only
mi
from
Loma Linda, CA
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
LLUCC - Records Management Only
mi
from
Loma Linda, CA
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
Florida Hospital
mi
from
Orlando, FL
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
Ochsner Clinic Foundation
mi
from
New Orleans, LA
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
Kresge Eye Institute
mi
from
Bingham Farms, MI
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
Kresge Eye Institute
mi
from
Bingham Farms, MI
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
Kresge Eye Institute
mi
from
Detroit, MI
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
Kresge Eye Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
Washington University Center for Advanced Medicine Infusion Center Pharmacy
mi
from
St. Louis, MO
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
Washington University Center for Advanced Medicine Infusion Center Pharmacy
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated:  2/25/2016
Macarthur Cancer Therapy Centre
mi
from
Campbelltown,
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Status: Enrolling
Updated: 2/25/2016
Macarthur Cancer Therapy Centre
mi
from
Campbelltown,
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Sutter East Bay Neuroscience Institute-Eden Medical Center
mi
from
Castro Valley, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Sutter East Bay Neuroscience Institute-Eden Medical Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Kaiser Permanente Los Angeles
mi
from
Los Angeles, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Kaiser Permanente Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Hoag Memorial Hospital Presbyterian
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
St. Joseph Hospital of Orange
mi
from
Orange, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
St. Joseph Hospital of Orange
mi
from
Orange, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of California, Irvine Medical Center
mi
from
Orange, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Kaiser Permanente-Redwood City
mi
from
Redwood City, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Kaiser Permanente-Redwood City
mi
from
Redwood City, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Sutter Institute for Medical Research
mi
from
Sacramento, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Sutter Institute for Medical Research
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Colorado Neurological Institute
mi
from
Englewood, CO
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Colorado Neurological Institute
mi
from
Englewood, CO
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Georgetown University Medical Center
mi
from
Washington,
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Florida
mi
from
Gainesville, FL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Memorial Cancer Institute
mi
from
Hollywood, FL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Memorial Cancer Institute
mi
from
Hollywood, FL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Mount Sinai Community Clinical Oncology Program
mi
from
Miami Beach, FL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Mount Sinai Community Clinical Oncology Program
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Piedmont Atlanta Hospital
mi
from
Atlanta, GA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Piedmont Atlanta Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Rush University Medical Center
mi
from
Chicago, IL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Illinois Cancer Care
mi
from
Peoria, IL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Cadence Cancer Center
mi
from
Warrenville, IL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Cadence Cancer Center
mi
from
Warrenville, IL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
IU Simon Cancer Center
mi
from
Indianapolis, IN
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
IU Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Kansas Cancer Center
mi
from
Westwood, KA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Markey Cancer Center-University of Kentucky
mi
from
Lexington, KY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Markey Cancer Center-University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Norton Cancer Institute
mi
from
Louisville, KY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Tufts Medical Center
mi
from
Boston, MA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Henry Ford Hospital
mi
from
Detroit, MI
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Spectrum Health
mi
from
Grand Rapids, MI
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Spectrum Health
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
John Nasseff Neuroscience Institute at Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
John Nasseff Neuroscience Institute at Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
ST. Luke's Hospital
mi
from
Kansas City, MO
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
ST. Luke's Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
The Brain Tumor Center at JFK Medical Center
mi
from
Edison, NJ
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
The Brain Tumor Center at JFK Medical Center
mi
from
Edison, NJ
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Overlook Hospital
mi
from
Summit, NJ
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Overlook Hospital
mi
from
Summit, NJ
Click here to add this to my saved trials